^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ERAS-601 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
Published date:
10/12/2022
Excerpt:
...we present results from monotherapy dose escalation cohorts in which patients received ERAS-601 continuously once a day (QD) or twice a day (BID) on a 28-day cycle....A confirmed partial response was observed in a patient with a BRAF class III mutation.
Trial ID:
